Saturday 17 October 2026
Export CANF’s income statement to Excel — free account
Can-Fite Biopharma Ltd
CANF Healthcare Biotechnology
Can-Fite Biopharma Ltd’s revenue for fiscal 2025 (year ended December 2025) was $405,000.00, down 39.9% from fiscal 2024.
1.76
0.09
−4.86%
Follow CANF
| Jun '26 | Jun '25 | Jun '24 | Sep '23 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | 0.00% | 0.00% | (140.94%) |
+8 more TTM periods Free account |
|
| 0.00% | 0.00% | 0.00% | (81.58%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
0.00% | 0.00% | 0.00% | (129.29%) | |
Average Days of Receivables |
— | — | — | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
(19.15) | (19.92) | (18.64) | — | |
Capital Expenditures |
(0.01) | (0.01) | (0.02) | — | |
| Other line items | |||||
Cash ROIC |
(160.99%) | (187.25%) | (258.71%) | 0.00% | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
— | — | — | 0.00 | |
Research and Development Expense of Revenue |
— | — | — | 915.12% | |
Selling, General and Administrative Expense of Revenue |
— | — | — | 390.01% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | — | — | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Depreciation/Fixed assets |
6.60 | 7.60 | 0.72 | 0.00 | |
Capex/Depreciation |
(0.24) | (0.32) | (0.83) | — | |
Revenue per Share |
— | — | — | 0.00 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates